Janux Therapeutics, Inc. (JANX) stock price, financials & research

Regular session · ET · Market data may be delayed.

GoAI snapshot

Jul 10, 2026

32/ 100

GoAI Score

Sell

Valuation

17

Overpriced

Sentiment

68

Bullish

Risk

70

High Risk

Momentum

47

Neutral

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

Company profile

Company website

Janux Therapeutics, Inc. is a biopharmaceutical company dedicated to developing innovative cancer therapies. The firm leverages its proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to create treatments designed to activate the body's T cells to fight tumors. Currently, Janux has several promising TRACTr product candidates in their early preclinical or discovery stages, which are engineered to target specific antigens such as prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2. In addition to its TRACTr pipeline, the company is also developing a Tumor Activated Immunomodulator (TRACIr) — a costimulatory bispecific candidate designed to enhance T cell anti-tumor activity by engaging with programmed death-ligand 1 and CD28. Furthermore, a specific focus for their EGFR-TRACTr program is addressing epidermal growth factor receptor, a target prevalent in many cancer types and already a focus of numerous approved monoclonal antibody treatments. Janux Therapeutics, Inc. was founded in 2017 and is headquartered in La Jolla, California.

Industry: Biotechnology
Sector: Healthcare
Headquarters: US
CEO: David Alan Campbell
Listed since: Jun 11, 2021
Employees: 113

Market position

Day range

Current $18.50

$17.30$18.91

52-week range

Current $18.50

$12.12$35.34

Open: $18.08
Previous close: $17.92
Volume: 1.5M; 1.55× average
Average volume: 969.41K; Average daily volume
Market cap: 1.13B USD
Beta: 2.39; Market reference 1
50-day average: $17.1885; +7.63% above average
200-day average: $15.0371; +23.03% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value: 824.95M USD
P/E (TTM): -11.21×
P/B (TTM): 1.25×
P/S (TTM): 47.01×
EV / EBITDA: -7.39×
Earnings yield: -13.29%
Free cash flow yield: -9.74%
Dividend yield: 0.00%

Profitability & efficiency

Gross margin: 100.00%
Operating margin: -598.15%
Net margin: -427.47%
Return on equity: -11.88%
Return on assets: -11.28%
Return on invested capital: -16.01%

Financial health

Debt / equity: 0.02×
Current ratio: 39.04×
Altman Z-score: 8.47
Piotroski F-score: 3 of 9

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin

Income trends

Revenue

10M USD-5.55%

Operating income

−157.67M USD-59.51%

Net income

−113.63M USD-64.69%

Financial statements: Income statement
Metric (USD)	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue	10M USD	10.59M USD	8.08M USD	8.61M USD	3.64M USD
Cost of goods sold	2.03M USD	2.06M USD	1.96M USD	841K USD	26.24M USD
Gross profit	7.97M USD	8.53M USD	6.13M USD	7.77M USD	−22.6M USD
Research and development	125.9M USD	68.39M USD	54.92M USD	53.44M USD	26.24M USD
Selling, general, and administrative	41.77M USD	41.05M USD	26.14M USD	22.26M USD	10.33M USD
Operating expenses	165.64M USD	107.38M USD	79.11M USD	74.86M USD	10.33M USD
Interest income	44.04M USD	29.85M USD	14.69M USD	4.03M USD	257K USD
Depreciation and amortization	2.03M USD	2.06M USD	1.96M USD	841K USD	113K USD
Operating income	−157.67M USD	−98.85M USD	−72.98M USD	−67.09M USD	−32.93M USD
Net income	−113.63M USD	−68.99M USD	−58.29M USD	−63.06M USD	−32.67M USD

Company facts updated Oct 8, 2026.

Earnings

EPS beat rate: 73%; 8 beats, 3 misses, 0 met estimates
Average EPS surprise: +12.76%; 11 comparable reports
Latest EPS result: -0.35; Estimate -0.25 · Miss by 39.28%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$28.25

52.70% upside

Past 12 months12-month forecastHigh $55.00Average $28.25Low $14.00

Rating distribution

16 ratings

Strong buy00%

Buy1275%

Hold319%

Sell16%

Strong sell00%

Recent analyst actions

12 institutions

Wolfe ResearchupgradePeer PerformOutperformAug 24, 2026

Jones TradingmaintainBuyApr 28, 2026

UBSdowngradeBuyNeutralApr 15, 2026

JANX news

defenseworld.netOct 6, 2026

Head-To-Head Review: Janux Therapeutics (NASDAQ:JANX) and Roivant Sciences (NASDAQ:ROIV)

Janux Therapeutics (NASDAQ: JANX - Get Free Report) and Roivant Sciences (NASDAQ: ROIV - Get Free Report) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on…

Read source

zacks.comSep 15, 2026

4 Prostate Cancer Drug Stocks to Watch During Awareness Month

Pfizer, Novartis, Janux Therapeutics and Candel Therapeutics offer varied prostate-cancer exposure, with established drugs and clinical or regulatory catalysts.

Read source

businesswire.comSep 14, 2026

Janux Therapeutics Announces First Patient Dosed in Phase 1 Study of JANX013

SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX), a clinical-stage biotechnology company developing tumor-activated immunotherapies, today announced that the first patient has been dosed in the Phase 1…

Read source

247wallst.comAug 24, 2026

Here Are Monday’s Top Wall Street Analyst Research Calls: AstraZeneca, Celestica, Chipotle Mexican Grill, Domino’s Pizza, Fortune Brands, Golar LNG, Jersey Mike’s Subs, Roku, and More

Wall Street analysts reshuffled the deck on Monday with a wave of upgrades, downgrades, and fresh initiations spanning pharma giants, fast-casual chains, and streaming players. Find out which names got bullish bets and…

Read source

zacks.comAug 21, 2026

JANX Shares Gain 19.1% in 3 Months: Here's What You Need to Know

Janux stock climbs 19.1% in three months as pipeline progress, upcoming catalysts and a strong cash position boost investor confidence.

Read source

zacks.comAug 6, 2026

Janux Therapeutics, Inc. (JANX) Reports Q2 Loss, Lags Revenue Estimates

Janux Therapeutics, Inc. (JANX) came out with a quarterly loss of $0.35 per share versus the Zacks Consensus Estimate of a loss of $0.26. This compares to a loss of $0.55 per share a year ago.

Read source